hypericum perforatum
Phase 2Small molecule
hypericum perforatum is one of 78 small molecule programs targeting Attention Deficit Hyperactivity Disorder. It is currently in Phase 2.
2
Indications
5
Total Trials
0
Active Trials
77
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
102 competitors in Attention Deficit Hyperactivity Disorder
#DrugCompanyPhaseTrials
1Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Ambien
PPurdue Pharma LP
Phase 3
OROS Oxybutynin
Johnson & JohnsonPhase 3
Catapres
Boehringer IngelheimPhase 3
Provigil
NNuvo Research GmbH
Phase 3
Sunosi
AAxsome Therapeutics, Inc.
Phase 3
Ritalin
PfizerPhase 3
Cymbalta
Alnylam PharmaceuticalsPhase 2
Adderall-XR
NNew River Pharmaceuticals
Phase 3
Concerta
Johnson & JohnsonPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Effectiveness1 trial
Effects of St. John's Wort on the Effectiveness of Oral Contraceptives
Completed·NNational Center for Complementary and Integrative Health (NCCIH)·N/A·NCT00026013·25 enrolled
Social Anxiety Disorder1 trial
St. John's Wort for the Treatment of Generalized Social Anxiety Disorder (GSAD)
Completed·NNational Center for Complementary and Integrative Health (NCCIH)·Phase 2/3·NCT00118833·56 enrolled
Patients With Solid Tumors1 trial
Attention Deficit Hyperactivity Disorder1 trial
Herbal Treatment for Attention Deficit Hyperactivity Disorder (ADHD)
Completed·NNational Center for Complementary and Integrative Health (NCCIH)·Phase 2·NCT00100295·59 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for hypericum perforatum. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details